FDA Approval: Encorafenib + Binimetinib in BRAF V600E NSCLC
Nov 06, 2023•42 min
Episode description
In this podcast, host Dr. Stephen Liu moderates a discussion a recent FDA approval and a specific molecular subtype of NSCLC. On October 11, 2023, the US FDA granted approval to encorafenib and binimetinib for advanced NSCLC harboring a BRAF V600E mutation based on the phase II PHAROS trial.
For the best experience, listen in Metacast app for iOS or Android
